Please try another search
For the six months ended 30 June 2017, Neuroderm Ltd revenues was not reported. Net loss increased from $12.3M to $28M. Higher net loss reflects General and administrative increase from $3M to $7.5M (expense), Research and development increase of 17% to $11.3M (expense), Financial expenses increase from $5K to $19K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.64 to -$1.28.
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -15.36 | -13.41 | -11.17 | -9.23 |
Net Income | -14.94 | -13.05 | -11.1 | -9.1 |
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Total Assets | 135.96 | 146.57 | 156.06 | 84.09 |
Total Liabilities | 7.6 | 6.78 | 6.49 | 5.26 |
Total Equity | 128.36 | 139.79 | 149.57 | 78.83 |
Period Ending: | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | -21.01 | -10.12 | -27.78 | -18.37 |
Cash From Investing Activities | -68.15 | -75.23 | -30.85 | 6.39 |
Cash From Financing Activities | 0.01 | 0 | 81.05 | 0.21 |
Net Change in Cash | -89 | -85.25 | 22.44 | -11.7 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review